(Q34593892)

3 August 2017

0 references

Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

Fábio L Rocha

1

1 reference

3 August 2017

Melissa G R Murad

2

1 reference

3 August 2017

Bárbara P Stumpf

3

1 reference

3 August 2017

Cláudia Hara

4

1 reference

3 August 2017

Cíntia Fuzikawa

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

20 February 2013

1 reference

Journal of Psychopharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

27

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

417-423

1 reference

Treatment of depressive symptoms in Parkinson's disease

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Imaging non-dopaminergic function in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Systematic review of antidepressant therapies in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

The neuropathological basis for depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Mortality in Parkinson's disease and its association with dementia and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

SSRIs in the treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Treatment of depression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

A controlled trial of antidepressants in patients with Parkinson disease and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

The impact of depressive symptoms in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

A systematic review of prevalence studies of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

Antidepressant studies in Parkinson's disease: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478282

21 January 2018

Identifiers

DOI

10.1177/0269881113478282

1 reference

3 August 2017

1 reference